

**CRR**  
JOURNAL  
OF CARDIORESPIRATORY RESEARCH

**ISSN 2181-0974**  
**DOI 10.26739/2181-0974**



**Journal of**  
**CARDIORESPIRATORY**  
**RESEARCH**



Volume 3, Issue 3

**2022**

МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ  
РЕСПУБЛИКИ УЗБЕКИСТАН

Журнал кардиореспираторных исследований

# JOURNAL OF CARDIORESPIRATORY RESEARCH

Главный редактор: Э.Н.ТАШКЕНБАЕВА

Учредитель:

Самаркандский государственный  
медицинский университет

Tadqiqot.uz

Ежеквартальный  
научно-практический  
журнал

ISSN: 2181-0974  
DOI: 10.26739/2181-0974



N<sup>o</sup> 3  
2022

## Главный редактор:

**Ташкенбаева Элеонора Негматовна**

*доктор медицинских наук, заведующая кафедрой внутренних болезней №2 Самаркандского Государственного медицинского университета, председатель Ассоциации терапевтов Самаркандской области. <https://orcid.org/0000-0001-5705-4972>*

## Заместитель главного редактора:

**Хайбулина Зарина Руслановна**

*доктор медицинских наук, руководитель отдела биохимии с группой микробиологии ГУ «РСНПМЦХ им. акад. В. Вахидова» <https://orcid.org/0000-0002-9942-2910>*

## ЧЛЕНЫ РЕДАКЦИОННОЙ КОЛЛЕГИИ:

**Аляви Анис Лютфуллаевич**

*академик АН РУз, доктор медицинских наук, профессор, Председатель Ассоциации Терапевтов Узбекистана, Советник директора Республиканского специализированного научно-практического центра терапии и медицинской реабилитации (Ташкент) <https://orcid.org/0000-0002-0933-4993>*

**Бокерия Лео Антонович**

*академик РАН, доктор медицинских наук, профессор, Президент научного центра сердечно-сосудистой хирургии им. А.Н. Бакулева (Москва), <https://orcid.org/0000-0002-6180-2619>*

**Курбанов Равшанбек Давлетович**

*академик АН РУз, доктор медицинских наук, профессор, Советник директора Республиканского специализированного научно-практического медицинского центра кардиологии (Ташкент), <https://orcid.org/0000-0001-7309-2071>*

**Шкляев Алексей Евгеньевич**

*д.м.н., профессор, ректор Федерального государственного бюджетного образовательного учреждения высшего образования «Ижевская государственная медицинская академия» Министерства здравоохранения Российской Федерации*

**Michał Tendera**

*профессор кафедры кардиологии Верхнесилезского кардиологического центра, Силезский медицинский университет в Катовице, Польша (Польша) <https://orcid.org/0000-0002-0812-6113>*

**Покушалов Евгений Анатольевич**

*доктор медицинских наук, профессор, заместитель генерального директора по науке и развитию сети клиник «Центр новых медицинских технологий» (ЦНМТ), (Новосибирск), <https://orcid.org/0000-0002-2560-5167>*

**Акилов Хабибулла Атауллаевич**

*доктор медицинских наук, профессор, Директор Центра развития профессиональной квалификации медицинских работников (Ташкент)*

**Ризаев Жасур Алимджанович**

*доктор медицинских наук, профессор, Ректор Самаркандского государственного медицинского университета, <https://orcid.org/0000-0001-5468-9403>*

**Абдиева Гулнора Алиевна**

*ассистент кафедры внутренних болезней №2 Самаркандского государственного медицинского университета, <https://orcid.org/0000-0002-6980-6278> (ответственный секретарь)*

**Зиядуллаев Шухрат Худойбердиевич**

*доктор медицинских наук, доцент, проректор по научной работе и инновациям Самаркандского Государственного медицинского университета <https://orcid.org/0000-0002-9309-3933>*

**Зуфаров Миржамол Мирумарович**

*доктор медицинских наук, профессор, руководитель отдела ГУ «РСНПМЦХ им. акад. В. Вахидова» <https://orcid.org/0000-0003-4822-3193>*

**Ливерко Ирина Владимировна**

*доктор медицинских наук, профессор, заместитель директора по науке Республиканского специализированного научно-практического медицинского центра фтизиатрии и пульмонологии Республики Узбекистан (Ташкент) <https://orcid.org/0000-0003-0059-9183>*

**Цурко Владимир Викторович**

*доктор медицинских наук, профессор Первого Московского государственного медицинского университета им. И.М. Сеченова (Москва) <https://orcid.org/0000-0001-8040-3704>*

**Камилова Умида Кабировна**

*д.м.н., профессор, заместитель директора по научной работе Республиканского специализированного научно-практического медицинского центра терапии и медицинской реабилитации (Ташкент) <https://orcid.org/0000-0002-1190-7391>*

**Тураев Феруз Фатхуллаевич**

*доктор медицинских наук, Директор Республиканского специализированного научно-практического медицинского центра эндокринологии имени академика Ю.Г. Туракулова*

**Саидов Максуд Арифович**

*к.м.н., директор Самаркандского областного отделения Республиканского специализированного научно-практического медицинского центра кардиологии (г. Самарканд)*

**Насирова Зарина Акбаровна**

*PhD, ассистент кафедры внутренних болезней №2 Самаркандского Государственного Медицинского университета (ответственный секретарь)*

## Bosh muharrir:

**Tashkenbayeva Eleonora Negmatovna**

*tibbiyot fanlari doktori, Samarqand davlat tibbiyot universiteti 2-sonli ichki kasalliklar kafedrasini mudiri,  
Samarqand viloyati vrachlar uyushmasi raisi.  
<https://orsid.org/0000-0001-5705-4972>*

## Bosh muharrir o'rinbosari:

**Xaibulina Zarina Ruslanovna**

*tibbiyot fanlari doktori, "akad V. Vohidov nomidagi RIJM davlat institutining mikrobiologiya guruhi  
bilan biokimyo kafedrasini mudiri" <https://orcid.org/0000-0002-9942-2910>*

## TAHRIRIYAT A'ZOLARI:

**Alyavi Anis Lyutfullayevich**

*O'zbekiston Respublikasi Fanlar akademiyasining akademigi, tibbiyot fanlari doktori, professor,  
O'zbekiston Terapevtlar uyushmasi raisi, Respublika ixtisoslashtirilgan ilmiy va amaliy tibbiy terapiya markazi va tibbiy reabilitatsiya direktori maslahatchisi  
(Toshkent), <https://orcid.org/0000-0002-0933-4993>*

**Bockeria Leo Antonovich**

*Rossiya fanlar akademiyasining akademigi, tibbiyot fanlari doktori, professor, A.N. Bakuleva nomidagi yurak-qon tomir jarrohligi ilmiy markazi prezidenti (Moskva)  
<https://orcid.org/0000-0002-6180-2619>*

**Kurbanov Ravshanbek Davlatovich**

*O'zbekiston Respublikasi Fanlar akademiyasining akademigi, tibbiyot fanlari doktori, professor,  
Respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazining direktor maslahatchisi (Toshkent)  
<https://orcid.org/0000-0001-7309-2071>*

**Shklyayev Aleksey Evgenievich**

*Tibbiyot fanlari doktori, professor, Rossiya Federatsiyasi Sog'liqni saqlash vazirligining "Izhevsk davlat tibbiyot akademiyasi" Federal davlat byudjeti oliy ta'lim muassasasi rektori*

**Mixal Tendra**

*Katovitsadagi Sileziya Tibbiyot Universiteti, Yuqori Sileziya Kardiologiya Markazi kardiologiya kafedrasini professori (Polsha)  
<https://orcid.org/0000-0002-0812-6113>*

**Pokushalov Evgeniy Anatolevich**

*tibbiyot fanlari doktori, professor, "Yangi tibbiy texnologiyalar markazi" (YTTM) klinik tarmog'ining ilmiy ishlar va rivojlanish bo'yicha bosh direktorining o'rinbosari  
(Novosibirsk) <https://orcid.org/0000-0002-2560-5167>*

**Akilov Xabibulla Ataulayevich**

*tibbiyot fanlari doktori, professor, Tibbiyot xodimlarining kasbiy malakasini oshirish markazi direktori (Toshkent)*

**Rizayev Jasur Alimjanovich**

*tibbiyot fanlari doktori, professor, Samarqand davlat tibbiyot universiteti rektori  
<https://orcid.org/0000-0001-5468-9403>*

**Abdiyeva Gulnora Aliyevna**

*Samarqand davlat tibbiyot universiteti 2-sonli ichki kasalliklar kafedrasini assistenti (mas'ul kotib)  
<https://orcid.org/0000-0002-6980-6278>*

**Ziyadullayev Shuxrat Xudoyberdiyevich**

*tibbiyot fanlari doktori, dotsent, Samarqand davlat tibbiyot universitetining fan va innovatsiyalar bo'yicha prorektori (Samarqand)  
<https://orcid.org/0000-0002-9309-3933>*

**Zufarov Mirjamol Mirumarovich**

*tibbiyot fanlari doktori, professor, "akad V. Vohidov nomidagi RIJM davlat muassasasi" bo'limi boshlig'i"  
<https://orcid.org/0000-0003-4822-3193>*

**Liverko Irina Vladimirovna**

*tibbiyot fanlari doktori, professor, Respublika ixtisoslashtirilgan fiziologiya va pulmonologiya ilmiy-amaliy tibbiyot markazining ilmiy ishlar bo'yicha direktor o'rinbosari (Toshkent)  
<https://orcid.org/0000-0003-0059-9183>*

**Surko Vladimir Viktorovich**

*tibbiyot fanlari doktori, professori I.M. Sechenov nomidagi Birinchi Moskva Davlat tibbiyot universiteti (Moskva)  
<https://orcid.org/0000-0001-8040-3704>*

**Kamilova Umida Kabirovna**

*tibbiyot fanlari doktori, professor, Respublika ixtisoslashtirilgan terapiya va tibbiy reabilitatsiya ilmiy-amaliy tibbiyot markazi ilmiy ishlari bo'yicha direktor o'rinbosari (Toshkent)  
<https://orcid.org/0000-0002-1190-7391>*

**Turayev Feruz Fatxullayevich**

*tibbiyot fanlari doktori, akademik Y.X.To'raqulov nomidagi Respublika ixtisoslashtirilgan endokrinologiya ilmiy amaliy tibbiyot markazi direktori  
<https://orcid.org/0000-0002-1321-4732>*

**Saidov Maqsud Arifovich**

*tibbiyot fanlari nomzodi, Respublika ixtisoslashgan kardiologiya ilmiy amaliy tibbiyot markazi Samarqand viloyat mintaqaviy filiali direktori (Samarqand)*

**Nasirova Zarina Akbarovna**

*Samarqand davlat tibbiyot instituti 2-sonli ichki kasalliklar kafedrasini assistenti, PhD (mas'ul kotib)*

## Chief Editor:

### **Tashkenbaeva Eleonora Negmatovna**

*Doctor of Medical Sciences, Head of the Department of Internal Diseases No. 2 of the Samarkand State Medical University, Chairman of the Association of Physicians of the Samarkand Region.*  
<https://orcid.org/0000-0001-5705-4972>

## Deputy Chief Editor:

### **Xaibulina Zarina Ruslanovna**

*Doctor of Medical Sciences, Head of the Department of Biochemistry with the Microbiology Group of the State Institution "RSSC named after acad. V. Vakhidov",* <https://orcid.org/0000-0002-9942-2910>

## MEMBERS OF THE EDITORIAL BOARD:

### **Alyavi Anis Lutfullaevich**

*Academician of the Academy of Sciences of the Republic of Uzbekistan, Doctor of Medical Sciences, Professor, Chairman of the Association of Physicians of Uzbekistan, Advisor to the Director of the Republican Specialized Scientific - Practical Center of Therapy and Medical Rehabilitation (Tashkent)*  
<https://orcid.org/0000-0002-0933-4993>

### **Bockeria Leo Antonovich**

*Academician of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, President of the Scientific Center for Cardiovascular Surgery named after A.N. Bakuleva (Moscow)*  
<https://orcid.org/0000-0002-6180-2619>

### **Kurbanov Ravshanbek Davletovich**

*Academician of the Academy of Sciences of the Republic of Uzbekistan, Doctor of Medical Sciences, Professor, Advisor to the Director Republican Specialized Scientific and Practical Medical Center of Cardiology, (Tashkent)*  
<https://orcid.org/0000-0001-7309-2071>

### **Shklyayev Aleksey Evgenievich**

*Doctor of Medical Sciences, Professor, Rector of the Federal State Budgetary Educational Institution of Higher Education "Izhevsk State Medical Academy" of the Ministry of Health of the Russian Federation*

### **Michal Tendera**

*Professor of the Department of Cardiology, Upper Silesian Cardiology Center, Silesian Medical University in Katowice, Poland (Poland)*  
<https://orcid.org/0000-0002-0812-6113>

### **Pokushalov Evgeny Anatolyevich**

*Doctor of Medical Sciences, Professor, Deputy Director General for Science and Development of the Clinic Network "Center for New Medical Technologies" (CNMT), (Novosibirsk)*  
<https://orcid.org/0000-0002-2560-5167>

### **Akilov Xabibulla Atullaevich**

*Doctor of Medical Sciences, Professor, Center for the development of professional qualifications of medical workers (Tashkent)*

### **Rizaev Jasur Alimjanovich**

*Doctor of Medical Sciences, Professor, Rector of the Samarkand State Medical University*  
<https://orcid.org/0000-0001-5468-9403>

### **Abdieva Gulnora Alievna**

*Assistant of the Department of Internal Diseases No. 2 of the Samarkand State Medical University*  
<https://orcid.org/0000-0002-6980-6278>  
**(Executive Secretary)**

### **Ziyadullaev Shuhrat Khudoyberdievich**

*Doctor of Medical Sciences, Associate Professor, Vice-Rector for Science and Innovation of the Samarkand State Medical University (Samarkand)*  
<https://orcid.org/0000-0002-9309-3933>

### **Zufarov Mirjamol Mirumarovich**

*Doctor of Medical Sciences, Professor, Head of the Department of the State Institution "RSNPMTSH named after acad. V. Vakhidov"*  
<https://orcid.org/0000-0003-4822-3193>

### **Liverko Irina Vladimirovna**

*Doctor of Medical Sciences, Professor, Deputy Director for Science of the Republican Specialized Scientific and Practical Medical Center for Phthysiology and Pulmonology of the Republic of Uzbekistan (Tashkent)*  
<https://orcid.org/0000-0003-0059-9183>

### **Tsurko Vladimir Viktorovich**

*Doctor of Medical Sciences, professor Of Moscow State Medical University by name I.M. Sechenov (Moscow)*  
<https://orcid.org/0000-0001-8040-3704>

### **Kamilova Umida Kabirovna**

*Doctor of Medicine, professor, deputy director of Scientific unit of the Republican specialized scientific and practical medical center for therapy and medical rehabilitation (Tashkent)*  
<https://orcid.org/0000-0002-1190-7391>

### **Turaev Feruz Fatxullaevich**

*Doctor of Medical Sciences, Director of the Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician Yu.G. Turakulova*

### **Saidov Maksud Arifovich**

*Candidate of Medical Sciences, Director of the Samarkand Regional Department of the Republican Specialized Scientific and Practical Medical Center of Cardiology (Samarkand)*

### **Nasyrova Zarina Akbarovna**

*PhD, Assistant of the Department of Internal Diseases No. 2 of the Samarkand State Medical University (Executive Secretary)*

**Алимов Дониёр Анварович**  
доктор медицинских наук, директор  
Республиканского научного центра  
экстренной медицинской помощи

**Янгиев Бахтиёр Ахмедович**  
кандидат медицинских наук,  
директор Самаркандского филиала  
Республиканского научного центра  
экстренной медицинской помощи

**Абдуллаев Акбар Хатамович**  
доктор медицинских наук, главный  
научный сотрудник Республиканского  
специализированного научно-практического  
центра медицинской терапии и  
реабилитации  
<https://orcid.org/0000-0002-1766-4458>

**Агабабян Ирина Рубеновна**  
кандидат медицинских наук, доцент,  
заведующая кафедрой терапии ФПДО,  
Самаркандского Государственного  
медицинского института

**Алиева Нигора Рустамовна**  
доктор медицинских наук, заведующая  
кафедрой Госпитальной педиатрии №1 с  
основами нетрадиционной медицины  
ТашПМИ

**Исмаилова Адолат Абдурахимовна**  
доктор медицинских наук, профессор,  
заведующая лабораторией  
фундаментальной иммунологии Института  
иммунологии геномики человека АН РУз

**Камалов Зайнитдин Сайфутдинович**  
доктор медицинских наук, профессор,  
заведующий лабораторией иммунорегуляции  
Института иммунологии и геномики  
человека АН РУз

**Каюмов Улугбек Каримович**  
доктор медицинских наук, профессор,  
заведующий кафедрой внутренних болезней  
и телемедицины Центра развития  
профессиональной квалификации  
медицинских работников

**Хусинова Шоира Акбаровна**  
кандидат философских наук, доцент,  
заведующая кафедрой общей практики,  
семейной медицины ФПДО Самаркандского  
Государственного медицинского института

**Шодиколова Гуландом Зикрияевна**  
д.м.н., профессор, заведующая кафедрой  
внутренних болезней № 3 Самаркандского  
Государственного Медицинского  
Института (Самарканд)  
<https://orcid.org/0000-0003-2679-1296>

**Alimov Doniyor Anvarovich**  
tibbiyot fanlari doktori, Respublika  
shoshilinch tibbiy yordam ilmiy markazi  
direktori (Toshkent)

**Yangiyev Baxtiyor Axmedovich**  
tibbiyot fanlari nomzodi,  
Respublika shoshilinch tibbiy  
yordam ilmiy markazining  
Samarqand filiali direktori

**Abdullaev Akbar Xatamovich**  
tibbiyot fanlari doktori, O'zbekiston  
Respublikasi Sog'liqni saqlash vazirligining  
"Respublika ixtisoslashtirilgan terapiya va  
tibbiy rehabilitatsiya ilmiy-amaliy  
tibbiyot markazi" davlat  
muassasi bosh ilmiy xodimi  
<https://orcid.org/0000-0002-1766-4458>

**Agababyan Irina Rubenovna**  
tibbiyot fanlari nomzodi, dotsent, DKTF,  
terapiya kafedrası mudiri, Samarqand  
davlat tibbiyot instituti

**Alieva Nigora Rustamovna**  
tibbiyot fanlari doktori, 1-sonli gospital  
pediatriya kafedrası mudiri, ToshPTI

**Ismoilova Adolat Abduraximovna**  
tibbiyot fanlari doktori, professor,  
O'zbekiston Respublikasi Fanlar  
akademiyasining Odam genomikasi  
immunologiyasi institutining fundamental  
immunologiya laboratoriyasining mudiri

**Kamalov Zaynitdin Sayfutdinovich**  
tibbiyot fanlari doktori, professor,  
O'zbekiston Respublikasi Fanlar  
akademiyasining Immunologiya va inson  
genomikasi institutining Immunogenetika  
laboratoriyasi mudiri

**Qayumov Ulug'bek Karimovich**  
tibbiyot fanlari doktori, professor, Tibbiyot  
xodimlarining kasbiy malakasini oshirish  
markazi, ichki kasalliklar va teletibbiyot  
kafedrası mudiri (Toshkent)

**Xusinova Shoira Akbarovna**  
tibbiyot fanlari nomzodi, dotsent,  
Samarqand davlat tibbiyot instituti DKTF  
Umumiy amaliyot va oilaviy tibbiyot  
kafedrası mudiri (Samarqand)

**Shodiqulova Gulandom Zikriyaevna**  
tibbiyot fanlari doktori, professor,  
Samarqand davlat tibbiyot instituti 3- ichki  
kasalliklar kafedrası mudiri (Samarqand)  
<https://orcid.org/0000-0003-2679-1296>

**Alimov Doniyor Anvarovich**  
Doctor of Medical Sciences, Director of the  
Republican Scientific Center of Emergency  
Medical Care

**Yangiev Bakhtiyor Axmedovich**  
PhD, Director of Samarkand branch of  
the Republican Scientific Center of  
Emergency Medical Care

**Abdullaev Akbar Xatamovich**  
Doctor of Medical Sciences,  
Chief Researcher of the State Institution  
"Republican Specialized Scientific and  
Practical Medical Center for Therapy and  
Medical Rehabilitation" of the Ministry of  
Health of the Republic of Uzbekistan,  
<https://orcid.org/0000-0002-1766-4458>

**Agababyan Irina Rubenovna**  
PhD, Associate Professor, Head of the  
Department of Therapy, FAGE, Samarkand  
State Medical Institute

**Alieva Nigora Rustamovna**  
Doctor of Medical Sciences, Head of the  
Department of Hospital Pediatrics No. 1 with  
the basics of alternative medicine, TashPMI

**Ismailova Adolat Abduraximovna**  
doctor of Medical Sciences, Professor, Head of  
the Laboratory of Fundamental Immunology of  
the Institute of Immunology of Human  
Genomics of the Academy of Sciences  
of the Republic of Uzbekistan

**Kamalov Zaynitdin Sayfutdinovich**  
doctor of Medical Sciences, Professor, Head of  
the Laboratory of Immunogenetics of the  
Institute of Immunology and Human Genomics  
of the Academy of Sciences of the  
Republic of Uzbekistan

**Kayumov Ulugbek Karimovich**  
Doctor of Medical Sciences, Professor,  
Head of the Department of Internal Diseases  
and Telemedicine of the Center for the  
development of professional qualifications  
of medical workers

**Khusinova Shoira Akbarovna**  
PhD, Associate Professor, Head of the  
Department of General Practice,  
Family Medicine FAGE of the  
Samarkand State Medical Institute

**Shodiqulova Gulandom Zikriyaevna**  
Doctor of Medical Sciences, professor, head of  
the Department of Internal Diseases N 3 of  
Samarkand state medical institute (Samarkand)  
<https://orcid.org/0000-0003-2679-1296>

## ОБЗОРНЫЕ СТАТЬИ/ АБИЙОТЛАР SHARHI/ REVIEW ARTICLES

1. **Исмаилов Ж.А.**  
Патогенетические аспекты осложнений при бронхообструктивном синдроме  
**Ismailov J.A.**  
Pathogenetic aspects of complications in broncho-obstructive syndrome  
**Ismailov J.A.**  
Bronxoobstruktiv sindromda asoratlar yuzaga kelishining patogenetik aspektlari..... 9
2. **Кодиров А.Э., Зиядуллаев Ш.Х., Ким А.А., Ташкенбаева Э.Н., Камалов З.С., Олимжонова Ф.Ж.**  
Клинические проявления, иммунопатогенез диффузного токсического зоба  
**Kodirov A.E., Ziyadullaev Sh.Kh., Kim A.A., Tashkenbayeva E.N., Kamalov Z.S., Olimjonova F.Zh.**  
Clinical manifestations, immunopathogenesis of diffuse toxic goiter  
**Kodirov A.E., Ziyadullaev Sh.X., Kim A.A., Tashkenbayeva E.N., Kamolov Z.S., Olimjonova F.J.**  
Diffuz zaharli buqoqning klinik ko'rinishi, immunopatogenezi..... 13

## ОРИГИНАЛЬНЫЕ СТАТЬИ/ ORIGINAL MAQOLALAR/ ORIGINAL ARTICLES

3. **Агабабян И.Р., Исмаилов Ж.А.**  
Методы раннего выявления и лечения осложнений хронической обструктивной болезни легких  
**Agababyan I.R., Ismailov J.A.**  
Methods for early detection and treatment of complications of chronic obstructive pulmonary disease  
**Agababyan I.R., Ismailov J.A.**  
O'pkaning surunkali obstruktiv kasalligida asoratlarni erta aniqlash va davolash usullari..... 19
4. **Агабабян И.Р., Исмоилова Ю.А.**  
Состояния на фоне длительного наблюдения больных с хронической сердечной недостаточностью  
**Agababyan I.R., Ismoilova Y.A.**  
Situation on the background of long-term follow-up of patients with chronic heart failure  
**Agababyan I.R., Ismoilova Y.A.**  
Surunkali yurak yetishmovchiligi bor bo'lgan bemorlarni uzoq muddatli kuzatish fonidagi ahvol..... 27
5. **Аляви Б.А., Абдуллаев А.Х., Далимова Д.А., Узоков Ж.К.**  
Антиагрегационная и гиполипидемическая терапия в лечении и реабилитации больных ишемической болезнью сердца после эндоваскулярного вмешательства  
**Alyavi B.A., A.Kh.Abdullaev, D.A.Dalimova, Zh.K.Uzokov**  
Antiaggregatory and hypolipidemic therapy in the treatment and rehabilitation of patients with coronary heart disease after endovascular intervention  
**Alyavi B.A., A.X.Abdullaev, D.A.Dalimova, Zh.K.Uzokov**  
Endovaskulyar aralashuvdan so'ng yurak iskemik kasalligi bilan og'rigan bemorlarni davolash va reabilitatsiya qilishda antiagregatsion va gipolipidemik terapiya..... 32
6. **Edyta Nabialek, Maciej Kazmierski**  
Кардиоваскулярные факторы риска и уровень экспрессии микроРНК у больных инфарктом миокарда  
**Edyta Nabialek, Maciej Kazmierski**  
Cardiovascular risk factors and expression level of microRNA in patients with myocardial infarction  
**Edyta Nabialek, Maciej Kazmierski**  
Miokard infarkti bo'lgan bemorlarda yurak-qon tomir xavf omillari va mikroRNKning ifoda darajasi..... 37
7. **Махманов Л.С., Исмоилова Ш.О., Абдухаликов О.З.**  
Диагностика и лечение витамин В12 дефицитной анемии, связанного с helicobacter pylori  
**Makhmanov L.S., Ismoilova Sh.O., Abdukhalikov O.Z.**  
Diagnosis and treatment of vitamin B12 deficiency anemia associated with helicobacter pylori  
**Makhmanov L.S., Ismoilova Sh.O., Abdukhalikov O.Z.**  
Helicobacter pylori bilan assotsiatsiyalangan vitamin B12 tanqisligi kamqonligini tashxislash va davolash..... 43
8. **Мухсинов Ф.М., Ливерко И.В.**  
Фенотипические предикторы и биомаркеры прогноза эффективности антимикробной терапии  
**Mukhsinov F.M., Liverko I.V.**  
Phenotypic predictors and biomarkers for forecasting the effectiveness of antimicrobial therapy  
**Muxsinov F.M., Liverko I.V.**  
Antimikrob terapiya samaradorligini bashorat qiluvchi fenotipik belgilar va biomarkerlar..... 54
9. **Насирова А.А.**  
Характеристики качества жизни больных бронхиальной астмой, хронической обструктивной болезнью легких и их сочетанием  
**Nasirova A.A.**  
Characteristics of the quality of life of patients with bronchial asthma, chronic obstructive pulmonary disease, and their combination  
**Nasirova A.A.**  
Bronxial astma va o'pkaning surunkali obstruktiv kasalligi va ularning kombinatsiyasi bilan og'rigan bemorlarning hayot sifatining xususiyatlari..... 59

|  |  |    |
|--|--|----|
| <b>10. Насырова З.А.</b>   | Роль полиморфизма локуса -819 C/T (rs1800871) гена IL-10 при дестабилизации ишемической болезни сердца у больных с нейросенсорными расстройствами  |    |
| <b>Nasyrova Z.A.</b>   | The role of IL-10 gene -819 C/T (rs1800871) polymorphism in destabilization of coronary heart disease in patients with neurosensory disorders  |    |
| <b>Nasirova Z.A.</b>   | Neurosensor buzilishlar kuzatilgan bemorlarda IL-10 geni -819 C/T (rs1800871) polimorfizmining yuragi koronar kasalligining nostabillanishidagi roli.....  | 66 |
| <b>11. Низов А.А., Дашкевич О.В., Сучкова Е.И., Куликова Н.А., Бирченко Н.С., Акулина М.В.</b> | Возможности коррекции метаболического синдрома фитоэктодистероидами  |    |
| <b>Nizov A.A., Dashkevich O.V., Suchkova E.I., Kulikova N.A., Birchenko N.S., Akulina M.V.</b> | Possibilities of the metabolic syndrome correction by phytoecdysteroids  |    |
| <b>Nizov A.A., Dashkevich O.V., Suchkova E.I., Kulikova N.A., Birchenko N.S., Akulina M.V.</b> | Fidoekdisterooidlar bilan metabolik sindromni tuzatish imkoniyatlari.....  | 71 |
| <b>12. Ниязова Ф.Н., Ливерко И.В.</b>  | Медицинские ошибки применения антибактериальных препаратов группы цефалоспоринов на амбулаторном этапе лечения   |    |
| <b>Niyazova F.N., Liverko I. V.</b>  | Medical mistakes in the use of antibacterial drugs of the cephalosporin group at the outpatient stage of treatment   |    |
| <b>Niyazova F.N., Liverko I.V.</b>   | Ambulator davolash bosqichida sefalosporin guruhi antibakterial preparatlarini qo'llashdagi tibbiy xatolar.....  | 77 |
| <b>13. Пулатов С.С., Камалова М.И.</b>   | Ранняя вертикализация больных с ишемическим инсультом на фоне ИБС  |    |
| <b>Pulatov S.S., Kamalova M.I.</b>   | Early verticalization of patients with ischemic stroke against the background of ischemic stroke   |    |
| <b>Пулатов С.С., Камалова М.И.</b>   | Yurak ishemik kasalligi fonida ishemik iinsult bo'lgan bemorlarni erta vertikalizasiya qilish.....   | 82 |
| <b>14. Ражабов Х.С., Ливерко И.В.</b>  | Чрезмерная дневная сонливость - предиктор психоэмоциональных нарушений и качества жизни больных хронической обструктивной болезнью легких  |    |
| <b>Rajabov K.S., Liverko I.V.</b>  | Excessive daytime sleepiness is a predictor of psychoemotional disorders and the quality of life of patients with chronic obstructive pulmonary disease  |    |
| <b>Rajabov X.S., Liverko I.V.</b>  | Haddan tashqari kunduzgi uyquchanlik - surunkali obstruktiv o'pka kasalligi bilan og'rigan bemorlarda psixoemotsional buzilishlar va hayot sifatini bashorat qilish belgisi.....                       | 85 |
| <b>15. Саидова М.М.</b>  | Доклинический процесс разработки лекарств механизмов ревматоидного артрита для изучения морфологических изменений структуры клеток и сосудов сердца у экспериментальных животных                       |    |
| <b>Saidova M.M.</b>  | Preclinical drug development process of rheumatoid arthritis mechanisms to study morphological changes in the cell and vascular structure of the heart in experimental animals                         |    |
| <b>Saidova M.M.</b>  | Ekperimentental hayvonlarda yurak hujayralari va qon tomirlari tuzilishidagi morfologik o'zgarishlarni o'rganish uchun klinikadan oldingi jarayonda revmatoid artrit mexanizmlarni ishlab chiqish..... | 91 |
| <b>16. Сулайманова Н.Э., Рахимова Х.М.</b>   | Оценка качества предоставляемых медицинских услуг по профилактике осложнений сердечно-сосудистых заболеваний   |    |
| <b>Sulaymanova N.E., Rakhimova H.M.</b>  | Assessment of the quality of medical services provided in the prevention of complications of cardiovascular diseases   |    |
| <b>Sulaymanova N.E., Rakhimova H.M.</b>  | Yurak qon tomir kasalliklari asoratlari profilaktikasida ko'rsatiladigan tibbiy xizmat sifatini baholash.....  | 94 |
| <b>17. Холиков И.Б., Ташкенбаева Э.Н.</b>  | Эхокардиографическая анатомия правого желудочка сердца: доступы визуализации   |    |
| <b>Kholikov I.B., Tashkenbaeva E.N.</b>  | Echocardiographic anatomy of the right ventricle: visualization accesses   |    |
| <b>Xolikov I.B., Tashkenbaeva E.N.</b>   | Yurak o'ng qorinchasining exokardiografik anatomiyasi: tekshirish yo'llari.....  | 98 |






**Edyta Nabialek**  
Отделение кардиологии и  
Структурные болезни сердца  
Медицинский университет Силезии  
Катовице, Польша  
**Maciej Kaźmierski**  
Отделение кардиологии и  
Структурные болезни сердца  
Медицинский университет Силезии  
Катовице, Польша

### ФАКТОРЫ СЕРДЕЧНО-СОСУДИСТОГО РИСКА И УРОВЕНЬ ЭКСПРЕССИИ МИКРОРНК У БОЛЬНЫХ ИНФАРКТОМ МИОКАРДА

**For citation:** Edyta Nabialek, Maciej Kaźmierski CARDIOVASCULAR RISK FACTORS AND EXPRESSION LEVEL OF MICRORNA IN PATIENTS WITH MYOCARDIAL INFARCTION. Journal of cardiorespiratory research. 2022, vol 3, issue 3, pp.37-42

 <http://dx.doi.org/10.5281/zenodo.7145891>

#### АННОТАЦИЯ

Сердечно-сосудистые факторы риска способствуют развитию сердечно-сосудистых заболеваний, и их присутствие может влиять на уровень экспрессии микроРНК у пациентов с инфарктом миокарда с подъемом сегмента ST. До сих пор было опубликовано лишь несколько сообщений, описывающих взаимосвязь между экспрессией микроРНК и наличием сердечно-сосудистых факторов риска.

#### Цель

Оценка экспрессии микроРНК у пациентов с инфарктом миокарда с подъемом сегмента ST и наличием сердечно-сосудистых факторов риска.

#### Материалы и методы

Обследовано 17 больных инфарктом миокарда с подъемом сегмента ST. Экспрессию микроРНК (miP-1, miP-208a и miP-423-5p) определяли по модели Пфаффа, а затем сравнивали между двумя группами: с факторами риска сердечно-сосудистых заболеваний и без них.

#### Полученные результаты

Более высокие уровни экспрессии микроРНК обнаружены у курильщиков. Более низкие уровни экспрессии miR-1, miR-208a и miR-423-5p были обнаружены у пациентов с повышенным уровнем липидов или у пациентов, принимающих гиполипемические препараты.

#### Вывод

Экспрессия микроРНК у пациентов с инфарктом миокарда с подъемом сегмента ST зависит от наличия некоторых сердечно-сосудистых факторов риска.

**Ключевые слова:** сердечно-сосудистые факторы риска, микроРНК, инфаркт миокарда.

**Edyta Nabialek**  
Department of Cardiology and  
Structural Heart Diseases  
Medical University of Silesia  
Katowice, Poland  
**Maciej Kaźmierski**  
Department of Cardiology and  
Structural Heart Diseases  
Medical University of Silesia  
Katowice, Poland

CARDIOVASCULAR RISK FACTORS AND EXPRESSION LEVEL OF MICRORNA IN PATIENTS WITH MYOCARDIAL INFARCTION

## ANNOTATION

Cardiovascular risk factors contribute to the development of cardiovascular disease and their presence may affect the level of microRNA expression in patients with ST-elevation myocardial infarction. So far, only a few reports have been published describing the relationship between microRNA expression and the presence of cardiovascular risk factors.

**Aim**

Evaluation of microRNA expression in patients with ST- elevation myocardial infarction with present cardiovascular risk factors.

**Materials & Methods**

Seventeen patients with ST-elevation myocardial infarction were examined. MicroRNA expression (miR-1, miR-208a i miR-423-5p) was determined according to the Pfaffla model and then compared between two groups: with and without cardiovascular risk factors.

**Results**

Higher expression levels of microRNAs were found in smokers. Lower levels of miR-1, miR-208a and miR-423-5p expression were found in patients with increased lipid levels or these using hypolipemic drugs.

**Conclusion**

MicroRNA expression in patients with ST-elevation myocardial infarction depends on the presence of some cardiovascular risk factors.

**Keywords:** Cardiovascular risk factors, microRNA, myocardial infarction.

**Edyta Nabialek**

Kardiologiya va Strukturaviy  
yurak kasalliklari bo'limi  
Sileziya tibbiyot universiteti  
Katovitse, Polsha

**Maciej Kazmierski**

Kardiologiya va Strukturaviy  
yurak kasalliklari bo'limi  
Sileziya tibbiyot universiteti  
Katovitse, Polsha

## MIOKARD INFARKTI BO'LGAN BEMORLARDA YURAK-QON TOMIR XAVF OMILLARI VA MIKRORNKNING IFODA DARAJASI

## ANNOTATSIYA

Yurak-qon tomir xavf omillari yurak-qon tomir kasalliklarining rivojlanishiga yordam beradi va ularning mavjudligi ST ko'tarilishi bilan miokard infarkti bo'lgan bemorlarda mikroRNK ifodasi darajasiga ta'sir qilishi mumkin. Hozirgacha mikroRNK ifodasi va yurak-qon tomir xavf omillarining mavjudligi o'rtasidagi munosabatni tavsiflovchi bir nechta hisobotlar nashr etilgan.

**Maqsad**

Hozirgi yurak-qon tomir xavf omillari bilan ST ko'tarilishi bilan miokard infarkti bo'lgan bemorlarda mikroRNK ifodasini baholash.

**Materiallar va usullar**

ST darajasi yuqori bo'lgan miokard infarkti bo'lgan 17 nafar bemor tekshirildi. MikroRNK ifodasi (miR-1, miR-208a i miR-423-5p) Pfaffla modeli bo'yicha aniqlandi va keyin ikki guruh o'rtasida taqqoslandi: yurak-qon tomir xavf omillari bilan va ularsiz.

**Natijalar**

Sigaret chekuvchilarda mikroRNKning yuqori ifoda darajasi aniqlangan. MiR-1, miR-208a va miR-423-5p ifodalarining past darajalari lipid darajasi ko'tarilgan yoki gipolipemik dorilarni qo'llagan bemorlarda topilgan.

**Xulosa**

ST balandligi miokard infarkti bo'lgan bemorlarda MikroRNK ifodasi yurak-qon tomir xavf omillarining mavjudligiga bog'liq.

**Kalit so'zlar:** yurak-qon tomir xavf omillari, mikroRNK, miokard infarkti.

About 99% of the human genome does not encode proteins but is transcriptionally highly active and give rise to a broad spectrum of non-coding RNAs (ncRNAs) with regulatory and structural functions.

Observation of ncRNAs fraction suggests their important role in humans. One of the many ncRNAs are microRNAs, novel regulators of cardiovascular risk factors and cell functions and thus candidates to improve diagnostic and prognostic assessment [1].

Cardiovascular risk factors contribute to the occurrence of cardiovascular diseases. Classic risk factors include lipid disorders, smoking, hypertension, diabetes, obesity, male sex, low physical activity. In addition, these factors can be divided in two groups: modifiable, which depend on the lifestyle, and non-modifiable, which are not affected by lifestyle or behavior [2].

MicroRNAs are short, single-stranded, non-coding ribonucleic acid molecules that negatively regulate gene expression. During myocardial infarction, microRNAs are released from damaged cardiomyocytes and their level of expression in the blood increases [3,4]. In patients with myocardial infarction presence of cardiovascular risk factors may affect the level of microRNA expression measured in blood.

The aim of this pilot study was to evaluate the expression level of selected microRNAs (miR-1, miR-208a and miR-423-5p) in patients with ST-elevation myocardial infarction with or without cardiovascular risk factors.

Such microRNAs were selected because they are crucial in the development of the heart, generation, and conduction of the stimuli and

in the development of cardiovascular diseases (including myocardial infarction) [5,6].

**Material & Methods**

Seventeen patients with ST-elevation myocardial infarction were included in the study. Age range was 18-85 years old. All patients signed informed consent to participate in this study.

ST-elevation myocardial infarction was diagnosed according to the current guidelines of the European Society of Cardiology [7]. A successful percutaneous coronary angioplasty was performed within six hours of the onset of myocardial infarction pain.

The exclusion criteria from participation in the study were as follows: history of acute coronary syndrome within 30 days prior to enrolment, percutaneous or surgical coronary revascularization within 30 days prior to enrolment, liver insufficiency, renal insufficiency, chronic heart failure, neoplasm, autoimmune disease, chronic obstructive pulmonary disease, active infection, pregnancy, myopathy, history of muscle trauma within 30 days prior to enrolment and lack of informed consent. Cardiovascular risk factors were defined as: arterial hypertension - systolic blood pressure of at least 140 mmHg and/or a diastolic blood pressure of at least 90 mm Hg [10], diabetes mellitus (DM2) – metabolic disease associated with hyperglycemia due to defect in insulin secretion and/or function [11], hyperlipidemia – total cholesterol and/or triglycerides above normal value (cholesterol >190 mg/dl, triglycerides >150 mg/dl) [12], smoking – persistent smoking

[13], positive family history – presence of ischemic heart disease in first degree male relatives under 55y or female relatives under 60y [14].

Blood samples were collected on hospital admission and 6, 12 and 24 hours after coronary angioplasty. Every patient had 5ml of blood acquired using sodium citrate-anti-coagulated specimens from ulnar vein, using the Vacutainer system. After that, blood samples were centrifuged within an hour at 4°C degrees for 10 minutes (1550xg). Supernatant was transferred to RNase / DNase free tubes and stored at -80° C until evaluation. RNA was isolated from these samples using the mirVana Paris Kit from Ambion, according to the manufacturer's instructions. Using the RT-PCR reaction (reverse transcription polymerase chain reaction), the template RNA was transcribed with reverse transcriptase into cDNA (complementary DNA). The material was then multiplied. The TaqMan MicroRNA Assays from Applied Biosystems on the 7900 HT Fast Real-Time PCR System from Applied Biosystems were used to study the expression level of selected microRNAs. The device calculates the value of the threshold cycles. Based on values obtained for the defined initial DNA concentrations, the efficiency of the polymerase chain reaction was determined from the slope of the standard curve. Then, normalization was performed to correct for differences between the compared trials. Test and reference samples were duplicated during normalization. Cel-miR-39 was used in

the study. The expression level of the test sample was compared to a calibrator of known expression level [8]. The relative expression level was calculated by the Pfaffel method [9].

Statistical Analysis

Statistical analysis was based on licensed MedCalc software (v. 14.8.1; MedCalc Software bvba, Ostend, Belgium). MicroRNA expression levels are shown as median and interquartile range (IQR; i.e. 25-75 pc). Qualitative variables (male sex, arterial hypertension, diabetes mellitus, positive family history, smoking, hyperlipidemia) were presented as absolute values. Intergroup differences were verified with Mann-Whitney U test. The criterion of statistical significance was established: p <0.05.

Results

Characteristics of patients with STEMI

Twelve men and five women were included in the study. Median age was 57, with the youngest being 40 and the oldest 84. Ten patients were diagnosed with arterial hypertension, nine of them were on pharmacological therapy and had good blood pressure control, seven patients had lipid disorders and used medicaments, eleven patients were smokers, and seven patients had a positive family history. No one were diagnosed with diabetes mellitus.

Table 1

Expression level of miR-1, miR-208a i miR-423-5p in STEMI group

| Time     | miR-1              | miR-208a            | miR-423-5p          |
|----------|--------------------|---------------------|---------------------|
| Baseline | 1,16 (1,070-1,542) | 1,03 (0,97-1,07)    | 1,055 (0,995-1,475) |
| 6 h      | 1,09 (0,935-1,210) | 1,02 (0,88-1,08)    | 1,03 (0,858-1,085)  |
| 12 h     | 1,11 (1,045-1,195) | 1,05 (1,01-1,08)    | 1,05 (0,973-1,072)  |
| 24 h     | 1,12 (1,022-1,165) | 1,035 (0,995-1,065) | 1,03 (0,955-1,06)   |

Baseline, '6 h', '12 h', '24 h' – Time marking points. Median values are shown, the interquartile range is given in brackets.

Table 2

miR-1 expression according to classical cardiovascular risk factors in patients with myocardial infarction

| Variable              |     | Time marking points    |                        |                                      |                                      |
|-----------------------|-----|------------------------|------------------------|--------------------------------------|--------------------------------------|
|                       |     | Baseline               | '6 h'                  | '12 h'                               | '24 h'                               |
| Male sex              | YES | 1,200<br>(1,078-1,633) | 1,095<br>(0,95-1,29)   | 1,125<br>(1,105-1,235)               | 1,090<br>(1,015-1,17)                |
|                       | NO  | 1,115<br>(1,08-1,145)  | 1,090<br>(0,92-1,163)  | 1,050<br>(0,978-1,183)               | 1,130<br>(1,042-1,173)               |
| Arterial hypertension | YES | 1,180<br>(1,06-1,61)   | 1,090<br>(0,94-1,12)   | 1,125<br>(0,96-1,21)                 | 1,120<br>(1,00-1,15)                 |
|                       | NO  | 1,130<br>(1,095-1,338) | 1,150<br>(0,89-1,40)   | 1,110<br>(1,102-1,175)               | 1,160<br>(1,06-1,175)                |
| Smoking               | YES | 1,180<br>(1,10-1,408)  | 1,090<br>(0,875-1,143) | <b>1,160*</b><br><b>(1,11-1,247)</b> | <b>1,160*</b><br><b>(1,06-1,203)</b> |
|                       | NO  | 1,130<br>(1,06-1,81)   | 1,145<br>(1,01-1,24)   | <b>0,995</b><br><b>(0,93-1,11)</b>   | <b>1,075</b><br><b>(0,97-1,12)</b>   |

|                         |     |                        |                        |                        |                                       |
|-------------------------|-----|------------------------|------------------------|------------------------|---------------------------------------|
| Hyperlipidemia          | YES | 1,340<br>(1,085-1,76)  | 1,090<br>(0,958-1,23)  | 1,110<br>(0,938-1,178) | <b>1,000*</b><br><b>(0,978-1,098)</b> |
|                         | NO  | 1,130<br>(1,055-1,19)  | 1,095<br>(0,92-1,15)   | 1,135<br>(1,10-1,21)   | <b>1,160</b><br><b>(1,13-1,21)</b>    |
| Positive family history | YES | 1,130<br>(1,10-1,34)   | 1,090<br>(0,918-1,187) | 1,110<br>(1,062-1,188) | 1,120<br>(1,038-1,153)                |
|                         | NO  | 1,180<br>(1,048-1,618) | 1,055<br>(0,94-1,24)   | 1,125<br>(0,96-1,21)   | 1,135<br>(1,00-1,18)                  |

\***p<0,05 (for the differences between groups defined by the presence of a risk factor, in the U Mann-Whitney test);** Baseline, '6 h', '12 h', '24 h' – Time marking points. Median values are shown, the interquartile range is given in brackets.

Evaluation of the differences in the miR-1 expression levels in patients with cardiovascular risk factors and without these factors demonstrated in people with smoking a significantly higher level of miR-1 expression at '12 h' and '24' hour after marking than in non-

smokers. On the other hand, patients with a history of hyperlipidemia had a significantly lower level of miR-1 expression at '24' hour than patients without hyperlipidemia.

Table 3

**miR-208a expression according to classical cardiovascular risk factors in the group of patients with myocardial infarction**

| Variable                |     | Time marking points                 |                        |                                       |                                     |
|-------------------------|-----|-------------------------------------|------------------------|---------------------------------------|-------------------------------------|
|                         |     | Baseline                            | '6 h'                  | '12 h'                                | '24 h'                              |
| Male sex                | YES | 1,050<br>(0,99-1,07)                | 1,020<br>(0,88-1,22)   | 1,055<br>(1,02-1,095)                 | 1,050<br>(0,992-1,068)              |
|                         | NO  | 0,97<br>(0,97-1,022)                | 0,97<br>(0,86-1,07)    | 1,025<br>(0,89-1,06)                  | 1,030<br>(0,953-1,06)               |
| Arterial hypertension   | YES | 0,99<br>(0,97-1,078)                | 1,010<br>(0,88-1,038)  | 1,050<br>(0,925-1,09)                 | 1,030<br>(0,94-1,075)               |
|                         | NO  | 1,035<br>(1,00-1,055)               | 1,060<br>(0,86-1,22)   | 1,050<br>(1,02-1,078)                 | 1,040<br>(1,00-1,058)               |
| Smoking                 | YES | <b>1,055*</b><br><b>(1,03-1,07)</b> | 0,975<br>(0,84-1,06)   | <b>1,070*</b><br><b>(1,022-1,102)</b> | 1,050<br>(1,00-1,09)                |
|                         | NO  | <b>0,97</b><br><b>(0,97-0,985)</b>  | 1,045<br>(0,945-1,15)  | <b>0,93</b><br><b>(0,877-1,05)</b>    | 1,005<br>(0,95-1,03)                |
| Hyperlipidemia          | YES | <b>0,97*</b><br><b>(0,97-0,985)</b> | 0,945<br>(0,845-1,115) | 1,03<br>(0,915-1,05)                  | <b>0,975*</b><br><b>(0,91-1,01)</b> |
|                         | NO  | <b>1,055</b><br><b>(1,03-1,07)</b>  | 1,035<br>(0,88-1,08)   | 1,070<br>(1,02-1,088)                 | <b>1,050</b><br><b>(1,03-1,09)</b>  |
| Positive family history | YES | 1,030<br>(0,985-1,038)              | 1,060<br>(0,833-1,115) | 1,050<br>(1,02-1,07)                  | 1,01<br>(1,00-1,038)                |

|  |        |                      |                       |                      |                       |
|--|--------|----------------------|-----------------------|----------------------|-----------------------|
|  | N<br>O | 1,030<br>(0,97-1,07) | 1,010<br>(0,88-1,085) | 1,045<br>(0,93-1,08) | 1,050<br>(0,98-1,075) |
|--|--------|----------------------|-----------------------|----------------------|-----------------------|

\*p<0,05 (for the differences between groups defined by the presence of a risk factor, in the U Mann-Whitney test); Baseline, '6 h', '12 h', '24 h' – Time marking points. Median values are shown, in the brackets the interquartile range is given.

When examining the differences of miR-208a expression levels in the myocardial infarction group comparing patients with or without cardiovascular risk factors, it was found that smokers were characterized by significantly higher levels of miR-208a expression at

'0 h' and '12' hour than non-smokers. Patients with a history of hyperlipidemia had significantly lower levels of miR-208a expression at '0 h' and '24' hour than those without hyperlipidemia.

Table 4

miR-423-5p expression according to classical cardiovascular risk factors in the group of patients with myocardial infarction

| Variable                |             | Time marking points    |                        |                                    |                                       |
|-------------------------|-------------|------------------------|------------------------|------------------------------------|---------------------------------------|
|                         |             | Baseline               | '6 h'                  | '12 h'                             | '24 h'                                |
| Male sex                | Y<br>E<br>S | 1,100<br>(0,988-1,487) | 1,025<br>(0,875-1,17)  | 1,055<br>(1,015-1,10)              | 1,015<br>(0,94-1,06)                  |
|                         | N<br>O      | 1,050<br>(1,022-1,197) | 1,030<br>(0,85-1,062)  | 0,98<br>(0,903-1,062)              | 1,03<br>(0,938-1,048)                 |
| Arterial hypertension   | Y<br>E<br>S | 1,060<br>(0,97-1,262)  | 1,025<br>(0,86-1,05)   | 1,040<br>(0,95-1,08)               | 1,015<br>(0,900-1,06)                 |
|                         | N<br>O      | 1,050<br>(1,02-1,588)  | 1,060<br>(0,84-1,24)   | 1,050<br>(1,012-1,068)             | 1,030<br>(0,973-1,058)                |
| Smoking                 | Y<br>E<br>S | 1,1<br>(1,02-1,487)    | 1,00<br>(0,828-1,058)  | <b>1,06*</b><br><b>(1,02-1,11)</b> | 1,050<br>(0,973-1,06)                 |
|                         | N<br>O      | 1,050<br>(0,97-1,175)  | 1,050<br>(1,02-1,13)   | <b>0,95</b><br><b>(0,88-1,05)</b>  | 0,985<br>(0,91-1,03)                  |
| Hyperlipidemia          | Y<br>E<br>S | 1,125<br>(0,98-1,50)   | 1,020<br>(0,895-1,115) | 1,020<br>(0,898-1,058)             | <b>0,910*</b><br><b>(0,893-0,992)</b> |
|                         | N<br>O      | 1,055<br>(1,01-1,45)   | 1,030<br>(0,85-1,06)   | 1,060<br>(1,01-1,08)               | <b>1,050</b><br><b>(1,03-1,06)</b>    |
| Positive family history | Y<br>E<br>S | 1,060<br>(1,02-1,44)   | 1,030<br>(0,865-1,068) | 1,050<br>(0,99-1,068)              | 1,00<br>(0,97-1,03)                   |
|                         | N<br>O      | 1,050<br>(0,97-1,462)  | 1,025<br>(0,86-1,13)   | 1,04<br>(0,95-1,08)                | 1,05<br>(0,91-1,06)                   |

\*p<0,05 (for the differences between groups defined by the presence of a risk factor, in the U Mann-Whitney test); '0', '6', '12', '24' – Time marking points. Median values are shown, the interquartile range is given in brackets.

When examining the differences in the levels of miR-423-5p expression between people with and without cardiovascular risk factors in the group of patients with myocardial infarction, it was found that the level of miR-423-5p expression at '12' hour was significantly higher in

smokers than in non-smokers. Patients with a history of hyperlipidemia had significantly lower levels of miR-423-5p expression at "24" hour than those not burdened with this risk factor.

Discussion

According to the results of the WOBASZ and NATPOL studies, the prevalence of cardiovascular risk factors in the Polish population is high [15].

In this study, a high frequency of arterial hypertension, hyperlipidemia and nicotine use was observed. Out of 17 subjects, 10 were diagnosed with arterial hypertension, 7 were diagnosed with lipid metabolism disorders, and 11 people were smokers.

The relevance between expression level of the studied microRNAs and the presence of certain cardiovascular risk factors was demonstrated. It has been observed that the expression levels of miR-1, miR-208a and miR-423-5p are higher in smokers than in non-smokers. On the other hand, patients with lipid metabolism disorders were characterized by a lower expression level of the investigated microRNAs compared to people with normal lipid levels. No influence of other cardiovascular risk factors on the expression of studied microRNAs was observed.

There are only a few reports available on this issue.

Ai found no correlation between level of miR-1 expression and sex or diabetes. The abovementioned author studied a large group of 93 patients with STEMI but also NSTEMI. Patients were of a similar age, people under 30 and over 75 were excluded, men dominated. The prevalence of diabetes mellitus was twice as high as in the described study. In addition, Ai presented the miR-1 expression level as a value for threshold cycles [16].

Similarly, Long has shown no correlation between the level of miR-1 expression and sex, diabetes, or smoking. The size of the study group was the same as in this study, what is more, Long qualified not only patients with STEMI but also NSTEMI. Age of the patients was similar,

most of them were men. Frequency of the risk factors was different - diabetes occurred twice as often, and cigarette smoking was observed more often than in this study. Nonetheless, Long obtained different results of the miR-1 expression study in patients with myocardial infarction [17].

On the contrary, Gao showed a relationship between some cardiovascular risk factors and the expression of miR-145. He described significantly lower levels of miR-145 expression in patients with diabetes and smoking. Gao studied expression of miR-145 because it is a particle specific to vascular smooth muscle cells, its expression level decreases in people with coronary artery disease. He conducted the study on a much larger group of people and qualified patients with STEMI, NSTEMI, stable and unstable coronary artery disease. The mean age was similar to the median in this analysis, the vast majority were men. The prevalence of cardiovascular risk factors was different. Gao used different methodology and obtained other miR-145 expression level results [18].

#### Results

This study suggested a correlation between some cardiovascular risk factors and the expression level of the studied microRNAs in patients with myocardial infarction. Higher levels of miRNA expression were observed in smokers than in non-smokers. In patients with increased lipid levels or those using hypolipemic drugs, the expression levels of miR-1, miR-208a and miR-423-5p were lower than in patients with normal lipid levels. There were no differences in the expression levels of the studied microRNAs for sex, hypertension, and positive family history.

#### References/Список литературы/Iqtiboslar

- Mattick JS, Taft RJ, Faulkner GJ.. A global view of genomic information—moving beyond the gene and the master regulator. *Trends Genet* 2010;26:21–28.
- Modrzejewski W, Musiał WJ. Stare i nowe czynniki ryzyka sercowo-naczyniowego – jak zahamować epidemię miażdżycy? Część I. Klasyfikacja czynników ryzyka. *Forum Zaburzeń Metabolicznych* 2010; 1(2): 106-114.
- Deddens JC, Colijn JM, Oerlemans MI, Pasterkamp G, Chamuleau SA, Doevendans PA, et al. Circulating MicroRNAs as Novel Biomarkers for the Early Diagnosis of Acute Coronary Syndrome. *J Cardiovasc Trans Res* 2013; 6: 884–898.
- D'Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. *Eur Heart J* 2010; 31: 2765–2773.
- Tijssen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al. MiR423-5p As a Circulating Biomarker for Heart Failure. *Circ Res* 2010; 106: 1035–1039.
- Olivieri F, Antonicelli R, Lorenzi M, D'Alessandra Y, Lazzarini R, Santini G, et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. *Int J Cardiol* 2013; 167: 531–536.
- Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; *J Am Coll Cardiol*. 2012;60:1581-98.
- The real-time polymerase chain reaction. Kubista M, Andrade JM, Bengtsson M, Forootan A, Jonák J, Lind K, et al. *Mol Aspects Med*. 2006;27:95-125.
- Pfaffl MW. A new mathematical model for relative quantification In Real-time RT-PCR. *Nucleic Acids Res* 2001; 29: 2002–2007.
- Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*. 2013;34:2159-219.
- Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart J*. 2013; 34: 3035-87.
- Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Eur Heart J*. 2012;33:1635-701.
- Carroll AJ, Labarthe DR, Huffman MD, Hitsman B. Global tobacco prevention and control in relation to a cardiovascular health promotion and disease prevention framework: A narrative review. *Prev Med*. 2016;93: 189-197.
- Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020;41:407-477.
- Piwońska A, Piotrowski W, Kozela M, Pająk A, Nadrowski P, Kozakiewicz K. et al. Cardiovascular diseases prevention in Poland: results of WOBASZ and WOBASZ II studies. *Kardiologia Pol.* 2018;76:1534-1541.
- Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. *Biochem Biophys Res Commun* 2010; 391: 73-77.
- Long G, Wang F, Duan Q, Chen F, Yang S, Gong W, et al. Human Circulating MicroRNA-1 and MicroRNA-126 as Potential Novel Indicators for Acute Myocardial Infarction. *Int J Biol Sci* 2012; 8: 811–818.
- Gao H, Guddeti RR, Matsuzawa Y, Liu LP, Su LX, Guo D, et al. Plasma Levels of microRNA-145 Are Associated with Severity of Coronary Artery Disease. *PLoS One*. 2015;10:e0123477. doi: 10.1371/journal.pone.0123477. eCollection 2015.

# ЖУРНАЛ КАРДИОРЕСПИРАТОРНЫХ ИССЛЕДОВАНИЙ

ТОМ 3, НОМЕР 3

## JOURNAL OF CARDIORESPIRATORY RESEARCH

VOLUME 3, ISSUE 3

**Контакт редакций журналов. [www.tadqiqot.uz](http://www.tadqiqot.uz)**

ООО Tadqiqot город Ташкент,  
улица Амира Темура пр.1, дом-2.

Web: <http://www.tadqiqot.uz/>; Email: [info@tadqiqot.uz](mailto:info@tadqiqot.uz)

Тел: (+998-94) 404-0000

**Editorial staff of the journals of [www.tadqiqot.uz](http://www.tadqiqot.uz)**

Tadqiqot LLC the city of Tashkent,  
Amir Temur Street pr.1, House 2.

Web: <http://www.tadqiqot.uz/>; Email: [info@tadqiqot.uz](mailto:info@tadqiqot.uz)

Phone: (+998-94) 404-0000